PSTC2501

PSTC2501 is a potent, highly selective, and brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome, currently under development for the treatment of obesity and cardiovascular diseases. By inhibiting the NLRP3 inflammasome, the drug prevents the maturation and secretion of proinflammatory cytokines IL-1β and IL-18, which are implicated in metabolic and inflammatory disorders. Preclinical studies in diet-induced obesity (DIO) mice have shown that PSTC2501 induces significant and sustained weight loss, particularly in fat mass, and its efficacy is further enhanced when used in combination with the GLP-1 receptor agonist semaglutide. The compound's high central nervous system (CNS) penetrance suggests that its weight-loss effects involve central target engagement. Additionally, PSTC2501 has demonstrated a reduction in inflammatory markers such as fibrinogen and was well-tolerated in toxicology studies, supporting its progression toward clinical trials.